Progress on anti-viral drugs and the application in military

LU Shunchao; YAN Lan

doi:10.3969/j.issn.1006-0111.2019.03.002

Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review, editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name

E-mail

Phone

Title

Content

Verification Code

Virus infection threatens human health.At present,the existing antiviral drugs have several problems including drug resistance and side effects.Thus,the study of new antiviral drugs has still become an urgent need in clinical practice.In this paper,some clinical commonly used and new antiviral drugs such as DNA polymerase inhibitor,reverse transcriptase inhibitor,protease inhibitor,integrase inhibitor,neuraminidase inhibitor,broad-spectrum antibacterial drugs and so on,were classified according to the different characteristics of antiviral drugs.This review also briefly introduced the application of antiviral drugs in military field.

Progress on anti-viral drugs and the application in military

1. Company 17 of Cadet Battalion 6, College of Basic Medical Sciences, School of Pharmacy, Naval Medical University, Shanghai 200433, China

2. Military Special Drug Research Center, School of Pharmacy, Naval Medical University, Shanghai 200433, China

Received Date: 2019-01-14

Rev Recd Date: 2019-04-16

Key words:

Abstract: Virus infection threatens human health.At present,the existing antiviral drugs have several problems including drug resistance and side effects.Thus,the study of new antiviral drugs has still become an urgent need in clinical practice.In this paper,some clinical commonly used and new antiviral drugs such as DNA polymerase inhibitor,reverse transcriptase inhibitor,protease inhibitor,integrase inhibitor,neuraminidase inhibitor,broad-spectrum antibacterial drugs and so on,were classified according to the different characteristics of antiviral drugs.This review also briefly introduced the application of antiviral drugs in military field.

HTML

Reference (23)

[1]	MARTINEZ J P,SASSE F,BRÖNSTRUP M M,et al.Antiviral drug discovery:broad-spectrum drugs from nature[J].Nat Prod Rep,2015,32(1):29-48.
[2]	WANG Y X,LI J X,HU Y M,et al.Ebola vaccines in clinical trial:the promising candidates[J].Human Vacc Immunother,2017,13(1):153-168.
[3]	杜红,赵柳红,覃忠于,等.HIV感染/AIDS住院患者高效抗逆转录病毒治疗中发生骨髓抑制致死亡的影响因素[J].中国药房,2015,26(35):4951-4954.
[4]	陈美钦,王长连.核苷类抗病毒药群体药动学研究及应用[J].海峡药学,2016,28(7):4-7.
[5]	DÉBORAH H,SAIK U,ELISABETH R,et al.Population pharmacokinetics of emtricitabine in human immunodeficiency virus type 1-infected pregnant women and their neonates[J].Antimicrob Agent,2009,53(3):1067-1073.
[6]	ELION R,MOLINA J M,RAMN ARRIBAS LPEZ J,et al.A randomized phase 3 study comparing once-daily elvitegravir with twice-daily raltegravir in treatment-experienced subjects with HIV-1 infection[J].J AIDS,2013,63(4):494-497.
[7]	杨庆坤,龙燕,陈典颜,等.PEG-IFN α-2a和利巴韦林联合自拟中药复方治疗慢性丙型肝炎的临床疗效[J].重庆医学,2017,46(32):4533-4536.
[8]	戴兆东,经继生,赵伟.普通干扰素联合利巴韦林治疗1b型丙肝患者疗效分析[J].东南大学学报(医学版),2017,36(6):1002-1004.
[9]	KAMATA M,LIU S,LIANG M,et al.Generation of human induced pluripotent stem cells bearing an anti-HIV transgene by a lentiviral vector carrying an internal murine leukemia virus promoter[J].Human Gene Therap,2010,21(11):1555-1567.
[10]	REGULES J A,BEIGEL J H,PAOLINO K M,et al.A recombinant vesicular stomatitis virus Ebola vaccine[J].N Engl J Med,2017,376(4):330-341.
[11]	SHUCHMAN M.Ebola vaccine trial in west Africa faces criticism[J].Lancet,2015,385(9981):1933-1934.
[12]	Agnandji S T,Huttner A,Zinser M E,et al.Phase 1 trials of rVSV Ebola vaccine in Africa and Europe[J].N Engl J Med,2016,374(17):1647-1660.
[13]	MEDAGLINI D,HARANDI A M,OTTENHOFF T H M,et al.Ebola vaccine R&D:filling the knowledge gaps[J].Sci Transl Med,2015,7(317):317ps24.
[14]	FELDMANN H,JONES S M,DADDARIO-DICAPRIO K M,et al.Effective post-exposure treatment of Ebola infection[J].PLoS Pathogens,2007,3(1):e2.
[15]	JACOBS M,AARONS E,BHAGANI S,et al.Post-exposure prophylaxis against Ebola virus disease with experimental antiviral agents:a case-series of health-care workers[J].Lancet Infect Dis,2015,15(11):1300-1304.
[16]	LI A Z,YU J Y,LU M J,et al.A Zika virus vaccine expressing premembrane-envelope-NS1 polyprotein[J].Nat Commun,2018,9:3067.
[17]	李静,戎庭军,张铭键,等.TLR7的研究进展[J].浙江临床医学,2015(2):315-317.
[18]	HEMMI H,KAISHO T,TAKEUCHI O,et al.Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway[J].Nat Immunol,2002,3(2):196-200.
[19]	MARTIN H J,LEE J M,WALLS D,et al.Manipulation of the toll-like receptor 7 signaling pathway by epstein-barr virus[J].J Virol,2007,81(18):9748-9758.
[20]	SUNG J A,PATEL S,CLOHOSEY M L,et al.HIV-specific,Ex vivo expanded T cell therapy:feasibility,safety,and efficacy in ART-suppressed HIV-infected individuals[J].Molecul Ther,2018,26(10):2496-2506.
[21]	MENDOZA P,GRUELL H,NOGUEIRA L,et al.Combination therapy with anti-HIV-1 antibodies maintains viral suppression[J].Nature,2018,561(7724):479-484.
[22]	赵旭,周辛波,钟武,等.抗病毒药物——法匹拉韦[J].临床药物治疗杂志,2015,13(4):16-20.
[23]	SHI F,LI Z,KONG L,et al.Synthesis and crystal structure of 6-fluoro-3-hydroxypyrazine-2-carboxamide[J].Drug Discov Ther,2014,8(3):117-120.

Message Board

Progress on anti-viral drugs and the application in military

doi: 10.3969/j.issn.1006-0111.2019.03.002

Abstract

References

Proportional views

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Related

Proportional views